Maharashtra FDA minister to hear on Thursday J&J's appeal on cancellation of licence

Fate of Jhonson & Jhonson's licence depends on the outcome of Thursday's hearing

Image
Sanjay Jog Mumbai
Last Updated : Jun 20 2013 | 1:33 AM IST
Maharashtra’s food and drug administration minister will hear on Thursday an appeal by Johnson & Johnson (J&J) against state Food and Drug Administration (FDA)’s move to cancel the company’s licence in April. The fate of the licence depends on the outcome of Thursday’s hearing.

FDA had issued the cancellation order on March 30 and J&J was given 90 days (up to June) to plead its case before the state. J&J’s licence for cosmetics at Mulund plant was cancelled by FDA, which expressed concerns over the ethylene oxide used during sterilisation that aimed to bring down microbial load in the same batch of baby powder produced in 2007.

FDA's had cancelled Johnson & Johnson India’s licence to manufacture cosmetics at its facility in Mulund, a Mumbai suburb.

Thursday's hearing was confirmed by both the office of Naik and FDA Commissioner Mahesh Zagde.  Zagde told Business Standard "Any action taken by licensing authority can be appealed to the state government. J&J has done so." However, J&J spokesman declined to comment.

It must be mentioned here that FDA's action was related to  a few batches of baby powder produced in 2007, the shelf life of which ended in July 2010. FDA had expressed concern over use of ethylene oxide for sterilization to bring down the microbial load.

FDA had said that the company did not conduct the mandatory test to ensure absence of traces of ethylene oxide, a carcinogenic substance before release of these batches. Since it was used in a product meant for infants, FDA observed, it was more objectionable. FDA had noted that  the company had carried out sterilization of 15 batches (of 160,000 retail containers) of baby powder by using ethylene oxide, against the normal practice of steam sterilization.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 20 2013 | 12:33 AM IST

Next Story